Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal Tumor
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal Tumor
Authors
Keywords
Imatinib, Gastrointestinal Stromal Tumor, Mitotic Rate, Adjuvant Imatinib, Primary Gist
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 20, Issue 2, Pages 593-599
Publisher
Springer Nature
Online
2012-10-01
DOI
10.1245/s10434-012-2682-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Natural History of Imatinib-naive GISTs
- (2011) Sabrina Rossi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients
- (2011) Basem Azab et al. ANNALS OF SURGICAL ONCOLOGY
- The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy
- (2011) Heikki Joensuu et al. Annual Review of Medicine
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
- (2011) Daniel Keizman et al. EUROPEAN JOURNAL OF CANCER
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- (2011) Nicolas F Delahaye et al. NATURE MEDICINE
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region
- (2010) P A Cassier et al. BRITISH JOURNAL OF CANCER
- High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
- (2010) S. C. H. Kao et al. CLINICAL CANCER RESEARCH
- Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors
- (2010) Daniel Perez et al. INTERNATIONAL JOURNAL OF CANCER
- Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
- (2010) JOURNAL OF CLINICAL ONCOLOGY
- Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Colorectal Liver Metastases Treated with Systemic Chemotherapy
- (2009) Yoji Kishi et al. ANNALS OF SURGICAL ONCOLOGY
- Natural Killer Cell IFN- Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
- (2009) C. Menard et al. CANCER RESEARCH
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
- (2009) Satoshi Teramukai et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
- (2009) Jason S Gold et al. LANCET ONCOLOGY
- Polymorphonuclear neutrophils and cancer: Intense and sustained neutrophilia as a treatment against solid tumors
- (2009) Juan Carlos Souto et al. MEDICINAL RESEARCH REVIEWS
- Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
- (2008) HanByoul Cho et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence
- (2008) Daniel Perez et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started